cover image European Journal of Neurology

European Journal of Neurology

2021 - Volume 28
Issue 4 | April 2021

Issue Information

Issue Information

SHORT COMMUNICATION

Background and purpose

The aim of our study is to review the relationship between NCSE and sCJD. Creutzfeldt–Jakob disease (CJD) is the most common form of human prion disease. Electroencephalography (EEG)‐detected changes such as periodic sharp wave complexes, superimposable to those seen in non‐convulsive epileptic status (NCSE), have only rarely been described at CJD onset, especially in sporadic CJD (sCJD) cases.

Methods

We describe clinical, EEG, cerebrospinal fluid (CSF) and neuroimaging findings of a confirmed case of sCJD with tau pathology, initially diagnosed as NCSE. We performed a literature review in PubMed of previous publications on both sCJD and NCSE.

Results

An 82‐year‐old woman with no medical history presented with a 2‐week rapidly progressive neurological disorder, with motor aphasia, myoclonus, pyramidalism, and left posterior alien hand. EEG showed periodic sharp waves on right frontal regions, so anti‐epileptic treatment was started. CSF results were normal. Brain magnetic resonance imaging demonstrated hyperintensity of the right cerebral cortex in diffusion sequences. Due to suspected new‐onset refractory status epilepticus (NORSE), corticosteroid treatment was started, without clinical improvement. Necropsy results confirmed sCJD with tau pathology. The literature review identified 14 references including a total of 18 cases with NCSE as the presenting symptom of sCJD; the clinical and results in complementary tests were compiled into a table.

Conclusions

Sporadic CJD should be considered in the differential diagnosis of patients with rapid cognitive decline and EEG changes consistent with NCSE. The wide heterogeneity in the etiology of NCSE, including autoimmune disorders, especially NORSE, suggests immunotherapy should be initiated based on a good risk–benefit balance. Some cases of sCJD, such as the present case with tau pathology, may mimic this clinico‐electrical course.

ORIGINAL ARTICLE

Background

Laing myopathy is characterized by broad clinical and pathological variability. They are limited in number and protocol of study. We aimed to delineate muscle imaging profiles and validate imaging analysis as an outcome measure.

Methods

This was a cross‐sectional and longitudinal cohort study. Data from clinical, functional and semi‐quantitative muscle imaging (60 magnetic resonance imaging [MRI] and six computed tomography scans) were studied. Hierarchical analysis, graphic heatmap representation and correlation between imaging and clinical data using Bayesian statistics were carried out.

Results

The study cohort comprised 42 patients from 13 families harbouring five mutations. The cohort had a wide range of ages, age at onset, disease duration, and myopathy extension and Gardner‐Medwin and Walton (GMW) functional scores. Intramuscular fat was evident in all but two asymptomatic/pauci‐symptomatic patients. Anterior leg compartment muscles were the only affected muscles in 12% of the patients. Widespread extension to the thigh, hip, paravertebral and calf muscles and, less frequently, the scapulohumeral muscles was commonly observed, depicting distinct patterns and rates of progression. Foot muscles were involved in 40% of patients, evolving in parallel to other regions with absence of a disto‐proximal gradient. Whole cumulative imaging score, ranging from 0 to 2.9 out of 4, was associated with disease duration and with myopathy extension and GMW scales. Follow‐up MRI studies in 24 patients showed significant score progression at a variable rate.

Conclusions

We confirmed that the anterior leg compartment is systematically affected in Laing myopathy and may represent the only manifestation of this disorder. However, widespread muscle involvement in preferential but variable and not distance‐dependent patterns was frequently observed. Imaging score analysis is useful to categorize patients and to follow disease progression over time.

SHORT COMMUNICATIONS

Background and purpose

Biomarkers reflecting the course of patients suffering from anti‐N‐methyl‐D‐aspartate receptor encephalitis (anti‐NMDARE) are urgently needed. Neurofilament light chains (NfL) have been studied as potential markers for neuroaxonal injury mainly in neuroinflammatory diseases, but so far there have been only in a few small reports on anti‐NMDARE. We aimed to compare the longitudinal course of cerebrospinal fluid (CSF)‐NfL levels and anti‐N‐methyl‐D‐aspartate receptor (anti‐NMDAR) antibodies with clinical parameters in six patients with anti‐NMDARE.

Methods

Longitudinal measurement of CSF‐NfL levels and CSF anti‐NMDAR antibodies in six patients suffering from anti‐NMDARE was performed.

Results

The major finding of this study is that most of our patients showed highly elevated NfL, with peak levels considerably delayed to clinical nadir. High NfL levels were associated with hippocampal atrophy but not with tumors detected. Furthermore, we did not find a clear relationship between NfL levels, CSF antibody titer, and CSF inflammatory markers.

Conclusions

CSF‐NfL levels do not predict short‐term outcome but rather are associated with intensive care unit stay and extreme delta brushes. However, high CSF‐NFL levels were associated with long‐term outcome. Our data suggest early aggressive immunotherapy to avoid primary and secondary neuroaxonal damage.

Original Article

Background

SMART (stroke‐like migraine attacks after radiation therapy) is a rare, delayed complication of brain radiation. In this study, we wanted to review the spectrum of symptoms, neuroradiological findings, autoimmune status, and outcomes in SMART syndrome patients.

Methods

We conducted a retrospective cohort study of all consecutive adult patients (≥18 years) diagnosed with SMART syndrome at Mayo Clinic, Rochester between January 1995 and December 2018.

Results

We identified 25 unique patients with SMART syndrome and a total of 31 episodes and 15 (60%) patients were male. The median age at onset was 46 (interquartile range [IQR] 43–55) years and the median latency of onset after the initial radiation was 21.6 (IQR 14.4–28.2) years. Magnetic resonance imaging (MRI) showed gyral edema and enhancement in all cases with the temporal (25, 80.6%) and parietal (23, 74.2%) lobes being the most commonly affected. The median follow‐up of the patients in our cohort was 10 (IQR 6–32) weeks. On univariate analysis, factors associated with an increased risk of recurrent SMART episodes were female gender (odds ratio [OR] 8.1, 95% confidence interval [95% CI] 1.1–52.6,  = 0.019) and absence of electrographic seizure discharges during initial symptoms (OR 7.4, 95% CI 1.1–45.9,  = 0.032). We could not identify an autoimmune etiology. Longer duration of symptoms (>10 weeks) correlated with an older age ( = 0.049), temporal lobe involvement ( < 0.001), and diffusion restriction ( = 0.043).

Conclusions

SMART is a syndrome with characteristic imaging findings and clinical features. Incomplete recovery by 10 weeks occurred in one‐third of individuals and was associated with older age, temporal lobe involvement, and restricted diffusion on MRI.

SHORT COMMUNICATION

Background and purpose

Blood pressure (BP) changes during alemtuzumab infusions are poorly understood. The aim of this study was to examine BP changes during alemtuzumab infusions in persons with multiple sclerosis (PwMS).

Methods

This was a retrospective cohort review of systolic (S) and diastolic (D) BP in PwMS receiving alemtuzumab.

Results

Thirty‐one patients were identified; 22 (64.5%) were women. Mean age and disease duration were 35.2 ± 7.1 and 9.2 ± 5.4 years, respectively. There was no history of hypertension or vascular events. Mean baseline SBP was 119.8 ± 15.1 mmHg, 118.8 ± 14.3 mmHg and 106.5 ± 6.1 mmHg whilst mean DBP was 75.3 ± 9.2 mmHg, 74.1 ± 12.4 mmHg and 69.2 ± 4.3 mmHg at doses 1, 6 and 9, respectively. During the first cycle, SBP increased by 19.2 ± 9.4 mmHg, with comparable percentage increases over the five infusions (16%, 22%, 17%, 11%, 13%, respectively). DBP increased by 6.2 ± 3.8 mmHg with similar percentage increases over the five infusions (8.4%, 11.5%, 5.5%, 7%, 3%). For the second cycle, SBP increased by 16.9 ± 3.2 mmHg, with similar increases over the 3 days (12%, 15%, 17%). DBP increased by 5.4 ± 4.2 mmHg (11%, 9%, 12.8%). The third cycle demonstrated increased mean and percentage of SBP and DBP by 8.9 ± 2.3 mmHg (10%, 70%, 11.8%) and 4.2 ± 1.9 mmHg (3%, 2%, 6.5%), respectively. Collectively, for 31 patients, in the first cycle, mean SBP increased from 119.8 ± 15.1 mmHg to 138.8 ± 13 mmHg ( ˂ 0.001, whilst mean DBP increased from 74.5 ± 9.2 mmHg to 79.2 ± 9.1 mmHg ( = 0.007). Overall, 17 (54.8%) patients had increasing BP by ≥20% and nine (29%) had increasing BP by ≥20 mmHg from baseline.

Conclusions

This demonstrates significant increases in BP during alemtuzumab infusions in PwMS.

SHORT COMMUNICATIONS

Background and purpose

Anti‐IgLON5 disease is a rare disorder characterized by a heterogeneous myriad of symptoms that may include sleep disorders, bulbar dysfunction, gait problems, movement disorders, cognitive impairment, oculomotor abnormalities, and nervous system hyperexcitability. Its physiopathology remains unknown, with a combination of both autoimmune and neurodegenerative findings.

Methods

We describe clinical, cerebrospinal fluid (CSF), and ioflupane single‐photon emission computed tomography (SPECT) findings of a positive case of anti‐IgLON5 disease mimicking probable progressive supranuclear palsy (PSP). We performed a literature review of previous publications reporting on anti‐IgLON5 disease and ioflupane SPECT.

Results

We report the case of a 66‐year‐old male who met clinical criteria for probable PSP, in whom ioflupane SPECT showed an alteration of the left presynaptic dopaminergic pathway. However, the presence of atypical neurological symptoms for PSP led to further complementary tests, and IgLON5 antibodies were detected in CSF. According to our literature review, ioflupane SPECT findings have been previously described in only three other patients with anti‐IgLON5 disease, with a reduced uptake in the striatum in two of them.

Conclusions

Ioflupane SPECT abnormalities, though scarcely described, are not uncommon in anti‐IgLON5 disease. They could be related to nigrostriatal dopaminergic degeneration in the context of the tauopathy component of the disease, but further case descriptions are necessary.

Original Article

Objective

We aimed to investigate the prevalence of , and variants as the cause of dystonia in a cohort of Spanish patients with isolated dystonia and in the literature.

Methods

A population of 2028 subjects (including 1053 patients with different subtypes of isolated dystonia and 975 healthy controls) from southern and central Spain was included. The genes , and were screened using a combination of high‐resolution melting analysis and direct DNA resequencing. In addition, an extensive literature search to identify original articles (published before 10 August 2020) reporting mutations in , or associated to dystonia was performed.

Results

Pathogenic or likely pathogenic variants in , and were identified in 0.48%, 0.57% and 0.29% of our patients, respectively. Five patients carried the variation p.Glu303del in . A very rare variant in (p.Ser238Asn) was found as a putative risk factor for dystonia.

Conclusions

There is a different genetic contribution to dystonia of these three genes in our patients (about 1.3% of patients) and in the literature (about 3.6% of patients), probably due the high proportion of adult‐onset cases in our cohort. As regards age at onset, site of dystonia onset, and final distribution, in our population there is a clear differentiation between DYT‐ and DYT‐, with DYT‐ likely to be an intermediate phenotype.

ORIGINAL ARTICLE

Background

The amnestic presentation of mild cognitive impairment (aMCI) represents the most common prodromal stage of Alzheimer's disease (AD) dementia. There is, however, some evidence of aMCI with typical amnestic syndrome but showing long‐term clinical stability. The ability to predict stability or progression to dementia in the aMCI condition is important, particularly for the selection of candidates in clinical trials. We aimed to establish the role of biomarkers, as assessed by cerebrospinal fluid (CSF) measures and [F]fluorodeoxyglucose (FDG)‐positron emission tomography (PET) imaging, in predicting prognosis in a large aMCI cohort.

Methods

We conducted a retrospective study, including 142 aMCI subjects who had a long follow‐up (4–19 years), baseline CSF data and [F]FDG‐PET scans individually assessed by validated voxel‐based procedures, classifying subjects into either limbic‐predominant or AD‐like hypometabolism patterns.

Results

The two aMCI cohorts were clinically comparable at baseline. At follow‐up, the aMCI group with a limbic‐predominant [F]FDG‐PET pattern showed clinical stability over a very long follow‐up (8.20 ± 3.30 years), no decline in Mini‐Mental State Examination score, and only 7% conversion to dementia. Conversely, the aMCI group with an AD‐like [F]FDG‐PET pattern had a high rate of dementia progression (86%) over a shorter follow‐up (6.47 ± 2.07 years). Individual [F]FDG‐PET hypometabolism patterns predicted stability or conversion with high accuracy (area under the curve = 0.89), sensitivity (0.90) and specificity (0.89). In the limbic‐predominant aMCI cohort, CSF biomarkers showed large variability and no prognostic value.

Conclusions

In a large series of clinically comparable subjects with aMCI at baseline, the specific [F]FDG‐PET limbic‐predominant hypometabolism pattern was associated with clinical stability, making progression to AD very unlikely. The identification of a biomarker‐based benign course in aMCI subjects has important implications for prognosis and in planning clinical trials.

ORIGINAL ARTICLE

Background

Uric acid (UA) is an important endogenous free radical scavenger that has been found to have a neuroprotective effect. However, there is uncertainty about the relationship between UA change and outcome in acute ischemic stroke (AIS) patients with reperfusion therapy.

Methods

We consecutively enrolled AIS patients with reperfusion therapy. UA was measured upon admission and during hospitalization. The change in UA levels (ΔUA) was determined by calculating the difference between admission UA and the lowest UA among all follow‐up measurements, with a positive ΔUA suggesting a decrease in UA levels. Functional outcome was assessed by modified Rankin Scale (mRS) at 3 months. Poor outcome was defined as mRS >2.

Results

A total of 361 patients were included (mean age 68.7 ± 13.9 years, 54.3% males). The mean UA on admission was 355 ± 96.1 μmol/L. The median ΔUA was 121 μmol/L (IQR 50–192 μmol/L) and 18 (5%) patients had increased UA levels. UA on admission was positively associated with good outcome ( for trend = 0.017). When patients were classified into quartiles by ΔUA, patients with the largest decrease in UA (Q4: 199–434 μmol/L) had a higher risk of poor outcome at 3 months compared to patients with the least decrease in UA (Q1: 0–57 μmol/L) (OR 2.55, 95% CI 1.09–5.98,  = 0.031). The risk of poor outcome increased with ΔUA ( for trend = 0.048).

Conclusions

In patients with reperfusion therapy, high UA on admission was associated with a good 3‐month outcome, while a greater decrease in UA was associated with poor outcome.

ORIGINAL ARTICLE

Background and purpose

Recent data suggest that imbalances in the composition of the gut microbiota (GM) could exacerbate the progression of Parkinson disease (PD). The effects of levodopa (LD) have been poorly assessed, and those of LD‐carbidopa intestinal gel (LCIG) have not been evaluated so far. The aim of this study was to identify the effect of LD and LCIG, in particular, on the GM and metabolome.

Methods

Fecal DNA samples from 107 patients with a clinical diagnosis of PD were analyzed by next‐generation sequencing of the V3 and V4 regions of the 16S rRNA gene. PD patients were classified in different groups: patients on LCIG (LCIG group,  = 38) and on LD (LD group,  = 46). We also included a group of patients ( = 23) without antiparkinsonian medicaments (Naïve group). Fecal metabolic extracts were evaluated by gas chromatography mass spectrometry.

Results

The multivariate analysis showed a significantly higher abundance in the LCIG group of , , and compared to the LD group. Compared to the Naïve group, the univariate analysis showed a reduction of and in the LD group. Moreover, an increase of , , and a reduction of , , and was found in the LCIG group. No significant difference was found in the multivariate analysis of these comparisons. The LD group and LCIG group were associated with a metabolic profile linked to gut inflammation.

Conclusions

Our results suggest that LD, and mostly LCIG, might significantly influence the microbiota composition and host/bacteria metabolism, acting as stressors in precipitating a specific inflammatory intestinal microenvironment, potentially related to the PD state and progression.

ORIGINAL ARTICLE

Background and purpose

The aim of this study was to investigate utilization rates, treatment pathways and survival prognosis in patients with amyotrophic lateral sclerosis (ALS) undergoing non‐invasive (NIV) and tracheostomy invasive ventilation (TIV) in a real‐world setting.

Methods

A prospective cohort study using a single‐centre register of 2702 ALS patients (2007 to 2019) was conducted. Utilization of NIV/TIV and survival data were analysed in three cohorts: (i) non‐NIV; (ii) NIV (NIV without subsequent TIV); and (iii) TIV (including TIV preceded by NIV).

Results

A total of 1720 patients with available data were identified, 72.0% of whom ( = 1238) did not receive ventilation therapy. NIV was performed in 20.8% of patients ( = 358). TIV was performed in 9.5% of patients ( = 164), encompassing both primary TIV (7.2%,  = 124) and TIV with preceding NIV (2.3%,  = 40). TIV was more often utilized without previous NIV (25.7% vs. 8.3% of all ventilated patients), demonstrating that primary TIV was the prevailing pathway for invasive ventilation. The median (range) survival was significantly longer in the NIV cohort (40.8 [37.2–44.3] months) and the TIV cohort (82.1 [68.7–95.6] months) as compared to the non‐NIV cohort (33.6 [31.6–35.7] months).

Conclusions

Although NIV represents the standard of care, its utilization rate was low. TIV was mainly started without preceding NIV, suggesting that TIV may not be confined to NIV treatment escalation. However, TIV was pursued in a minority of patients who had previously undergone NIV. The survival benefit observed in the patients with NIV was equal to that reported in a controlled pivotal trial, but the prognosis with TIV is highly variable. The determinants of utilization of NIV/TIV and of survival (bulbar syndrome, availability of ventilation‐related home nursing, cultural factors) warrant further investigation.

Review

Abstract

Numerous neuroimaging techniques have been used to identify biomarkers of disease progression in Huntington's disease (HD). To date, the earliest and most sensitive of these is caudate volume; however, it is becoming increasingly evident that numerous changes to cortical structures, and their interconnected networks, occur throughout the course of the disease. The mechanisms by which atrophy spreads from the caudate to these cortical regions remains unknown. In this review, the neuroimaging literature specific to T1‐weighted and diffusion‐weighted magnetic resonance imaging is summarized and new strategies for the investigation of cortical morphometry and the network spread of degeneration in HD are proposed. This new avenue of research may enable further characterization of disease pathology and could add to a suite of biomarker/s of disease progression for patient stratification that will help guide future clinical trials.

ORIGINAL ARTICLE

Background and purpose

Pathogenic variants in have been reported to date to be causative in three unrelated families with autosomal recessive intermediate Charcot‐Marie‐Tooth disease (CMT) and in one consanguineous family with spinal muscular atrophy (SMA). is known to be expressed in the human peripheral nervous system, and previous studies have shown its function in axon terminal autophagy of synaptic vesicles, lending support to its underlying pathogenetic mechanism. Despite this, there is limited knowledge of the clinical and genetic spectrum of disease.

Methods

We leverage the diagnostic utility of exome and genome sequencing and describe novel biallelic variants in in 13 individuals from nine unrelated families originating from four different countries. We compare our phenotypic and genotypic findings with a comprehensive review of cases previously described in the literature.

Results

We found that patients presented with variable disease severity at different ages of onset (8–25 years). In our cases, weakness usually started proximally, progressing distally, and can be associated with intermediate slow conduction velocities and minor clinical sensory involvement. We report three novel nonsense and four novel missense pathogenic variants associated with these ‐associated neuropathies, which are phenotypically spinal muscular atrophy (SMA) or intermediate Charcot‐Marie‐Tooth disease.

Conclusions

‐associated neuropathies should be considered as an important differential in non‐5q SMAs even in the presence of mild sensory impairment and a candidate causative gene for a wide range of hereditary neuropathies. We present this series of cases to further the understanding of the phenotypic and molecular spectrum of ‐associated diseases.

ORIGINAL ARTICLE

Background and purpose

Remote ischaemic per‐conditioning (RIC) is neuroprotective in experimental ischaemic stroke. Several neurohumoral, vascular and inflammatory mediators are implicated. The effect of RIC on plasma biomarkers was assessed using clinical data from the REmote ischaemic Conditioning After Stroke Trial (RECAST‐1).

Methods

RECAST‐1 was a pilot sham‐controlled blinded trial in 26 patients with ischaemic stroke, randomized to receive four 5‐min cycles of RIC within 24 h of ictus. Plasma taken pre‐intervention, immediately post‐intervention and on day 4 was analysed for nitric oxide (nitrate/nitrite) using chemiluminescence and all other biomarkers by multiplex analysis. Biomarkers were correlated with clinical outcome (day 90 National Institutes of Health Stroke Scale, modified Rankin Scale, Barthel index).

Results

Remote ischaemic per‐conditioning reduced serum amyloid protein (SAP) and tissue necrosis factor α (TNF‐α) levels from pre‐ to post‐intervention ( = 13, two‐way ANOVA,  < 0.05). Overall ( = 26), increases in SAP pre‐ to post‐intervention and pre‐intervention to day 4 were moderately correlated with worse day 90 clinical outcomes. No consistent significant changes over time, or by treatment, or correlations with outcome were seen for other biomarkers.

Conclusions

Remote ischaemic per‐conditioning reduced SAP and TNF‐α levels from pre‐ to post‐intervention. Increases in plasma levels of SAP were associated with worse clinical outcomes after ischaemic stroke. Larger studies assessing biomarkers and the safety and efficacy of RIC in acute ischaemic stroke are warranted to further understand these relationships.

ORIGINAL ARTICLE

Background and purpose

Clinical outcomes vary substantially among individuals with large vessel occlusion (LVO) stroke. A small infarct core and large imaging mismatch were found to be associated with good recovery. The aim of this study was to investigate whether those imaging variables would improve individual prediction of functional outcome after early (<6 h) endovascular treatment (EVT) in LVO stroke.

Methods

We included 222 patients with acute ischemic stroke due to middle cerebral artery (MCA)‐M1 occlusion who received EVT. As predictors, we used clinical variables and region of interest (ROI)‐based magnetic resonance imaging features. We developed different machine‐learning models and quantified their prediction performance according to the area under the receiver‐operating characteristic curves and the Brier score.

Results

The rate of successful recanalization was 78%, with 54% patients having a favorable outcome (modified Rankin scale score 0–2). Small infarct core was associated with favorable functional outcome. Outcome prediction improved only slightly when imaging was added to patient variables. Age was the driving factor, with a sharp decrease in likelihood of favorable functional outcome above the age of 78 years.

Conclusions

In patients with MCA‐M1 occlusion strokes referred to EVT within 6 h of symptom onset, infarct core volume was associated with outcome. However, ROI‐based imaging variables led to no significant improvement in outcome prediction at an individual patient level when added to a set of clinical predictors. Our study is in concordance with current practice, where imaging mismatch or collateral readouts are not recommended as factors for excluding patients with MCA‐M1 occlusion for early EVT.

ORIGINAL ARTICLE

Aim

Involvement of the corpus callosum has been identified as a feature of amyotrophic lateral sclerosis (ALS), particularly through neuropathological studies. The aim of the present study was to determine whether alteration in transcallosal function contributed to the development of ALS, disease progression and thereby functional disability.

Methods

Transcallosal function and motor cortex excitability were assessed in 17 ALS patients with results compared to healthy controls. Transcallosal inhibition (interstimulus intervals (ISI) of 8–40 ms), short interval intracortical facilitation (SICF) and inhibition (SICI) were assessed in both cerebral hemispheres. Patients were staged utilising clinical and neurophysiological staging assessments.

Results

In ALS, there was prominent reduction of transcallosal inhibition (TI) when recorded from the primary and secondary motor cortices compared to controls ( = 23.255,  < 0.001). This reduction of TI was accompanied by features indicative of cortical hyperexcitability, including reduction of SICI and increase in SICF. There was a significant correlation between the reduction in TI and the rate of disease progression ( = −0.825,  < 0.001) and reduction in muscle strength ( = 0.54,  = 0.031).

Conclusion

The present study has established that dysfunction of transcallosal circuits was an important pathophysiological mechanism in ALS, correlating with greater disability and a faster rate of disease progression. Therapies aimed at restoring the function of transcallosal circuits may be considered for therapeutic approaches in ALS.

ORIGINAL ARTICLE

Background and purpose

Myelitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody (MOG‐ab)‐associated disease (MOGAD) and aquaporin‐4 antibody (AQP4‐ab)‐positive neuromyelitis optica spectrum disorder (NMOSD). The aim of this work was to evaluate the differentiating features of myelitis between the two diseases.

Methods

Myelitis‐related clinical and radiologic data from 130 patients with MOGAD and 125 patients with AQP4‐ab–positive NMOSD were retrospectively reviewed and compared. A scoring model was established to differentiate MOG‐ab–associated myelitis from AQP4‐ab–associated myelitis.

Results

Overall, 29.2% (38/130) of patients with MOGAD and 66.4% (83/125) of patients with AQP4‐ab–positive NMOSD had ever experienced myelitis. Compared with those with NMOSD, patients with MOGAD exhibited a lower frequency of myelitis, either during the first episode ( < 0.0001) or throughout the disease duration ( < 0.0001). Compared with AQP4‐ab–associated myelitis, MOG‐ab–associated myelitis manifested a higher male‐to‐female ratio ( < 0.0001), younger age at disease onset ( = 0.0004), more prodromic influenza‐like symptoms ( = 0.030), more prodromic fever ( = 0.0003), more bowel and bladder dysfunction ( = 0.011), less painful tonic spasms ( < 0.0001), and lower Expanded Disability Status Scale scores after treatment ( < 0.0001). On magnetic resonance imaging, lower spinal cord lesions ( = 0.023), short‐segment lesions ( = 0.021), conus involvement ( = 0.0001), and H sign ( < 0.0001) were more common in MOG‐ab–associated myelitis. A scoring model with a cutoff value of 4 differentiated MOG‐ab–associated myelitis from AQP4‐ab–associated myelitis with a sensitivity of 87.9% and a specificity of 90.1%.

Conclusions

Myelitis was less commonly observed in MOGAD and exhibited distinct features compared to those of AQP4‐ab–positive NMOSD.

ORIGINAL ARTICLE

Background and purpose

Human prion diseases (PrDs) are a group of fatal and transmissible neurodegenerative disorders that are diagnosed definitively in post mortem brains. Calmodulin (CaM) is a ubiquitous calcium‐binding protein. Increased brain CaM level has been reported in prion‐infected rodent models and some scrapie‐infected cells. However, the putative alteration of CaM in cerebrospinal fluid (CSF) of human PrDs is uncertain. Here, we try to figure out the profiles of CSF CaM in sporadic Creutzfeldt‐Jacob disease.

Methods

Cerebrospinal fluid samples of 40 Chinese patients with probable sporadic Creutzfeldt‐Jacob disease (sCJD) and 40 cases without sCJD (non‐PrDs) were recruited in this study. The presence of CaM in the CSF was assessed by Western blot, while total tau levels were measured using an enzyme‐linked immunosorbent assay kit. In addition, the presence of CaM in another CSF panel consisting of 30 definite sCJD cases and 30 non‐PrD cases was evaluated using CaM‐specific Western blot analysis.

Results

Cerebrospinal fluid CaM positivity was observed in 28/40 cases of probable sCJD and in 9/40 non‐PrD cases. The CSF tau levels in the probable sCJD cases were markedly higher than those in the non‐PrD cases. Logistic regression established a significant correlation between CSF CaM signal and total CSF tau level. Similar results were observed in the panel of cases with definite sCJD: the rates of CSF CaM positivity in the definite sCJD cases and the non‐PrD cases were 22/30 and 6/30, respectively.

Conclusions

Although CSF CaM positivity might not be a sCJD‐specific phenomenon, a significantly high rate of CaM‐positive CSF in sCJD cases, especially in those with high CSF tau levels, rendered it a valuable diagnostic biomarker for sCJD.

ORIGINAL ARTICLE

Background and purpose

Human immunodeficiency virus (HIV)‐associated neurological syndromes occur in affected individuals as a consequence of primary HIV infection, opportunistic infections, inflammation and as an adverse effect of some forms of antiretroviral treatment (ART). The aim of this systematic review was to establish the epidemiological characteristics, clinical features, pathogenetic mechanisms and risk factors of HIV‐related peripheral neuropathy (PN).

Methods

A systematic, computer‐based search was conducted using the PubMed database. Data regarding the above parameters were extracted. Ninety‐four articles were included in this review.

Results

The most commonly described clinical presentation of HIV neuropathy is the distal predominantly sensory polyneuropathy. The primary pathology in HIVPN appears to be axonal rather than demyelinating. Age and treatment with medications belonging in the nucleoside analogue reverse transcriptase class are risk factors for developing HIV‐related neuropathy. The pooled prevalence of PN in patients naïve to ARTs was established to be 29% (95% CI: 9%–62%) and increased to 38% (95% confidence interval [CI]: 29%–48%) when looking into patients at various stages of their disease. More than half of patients with HIV‐related neuropathy are symptomatic (53%, 95% CI: 41%–63%). Management of HIV‐related neuropathy is mainly symptomatic, although there is evidence that discontinuation of some types of ART, such as didanosine, can improve or resolve symptoms.

Conclusions

Human immunodeficiency virus–related neuropathy is common and represents a significant burden in patients’ lives. Our understanding of the disease has grown over the last years, but there are unexplored areas requiring further study.

ORIGINAL ARTICLE

Background and purpose

Steroid‐responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a rare condition defined by encephalopathy with acute or subacute onset, the presence of serum anti‐thyroid antibodies, and reasonable exclusion of alternative causes. Despite having strong response towards corticosteroid treatment, some patients exhibit a chronic‐relapsing course and require long‐term immunosuppression. Markers for early identification of those patients are still absent. Thus, we aimed to characterise clinical as well as laboratory parameters of our local SREAT cohort.

Methods

We retrospectively evaluated a cohort of 22 SREAT patients treated in our hospital from January 2014.

Results

A total of 14 patients with a monophasic disease course and eight patients with multiple relapses were identified. Neither baseline characteristics nor routine cerebrospinal fluid (CSF) parameters were able to distinguish between those patient groups. Flow cytometry following initial relapse therapy showed treatment‐resistant sequestration of activated CD4+ T cells in patients with a relapsing disease course, whereas other lymphocyte subsets showed uniform changes. Such changes were also present in long‐term follow‐up CSF examination.

Conclusion

Our findings indicate a potential biomarker for risk stratification in patients with SREAT. Currently, it remains unclear whether the observed two phenotypes are different spectra of SREAT or represent separate diseases in terms of pathophysiology.

ORIGINAL ARTICLE

Abstract

Background and purpose: Recently, some emerging cerebrospinal fluid (CSF) markers have been proposed as diagnostic tools for Alzheimer disease (AD) that can have an effect on disease progression. We analyze the accuracy of these CSF markers for diagnosis of AD in reference to brain amyloid positron emission tomography (PET). We also investigated whether they help in differentiating AD from other dementias and examined their influence in tracing the progression to dementia. Methods: Amyloid‐β (Aβ) 1–42, total tau (t‐tau), phosphorylated tau, Aβ, Aβ, beta‐site amyloid precursor protein cleaving enzyme 1 (BACE‐1), neurogranin (ng), phosphorylated neurofilament heavy‐chain, and α‐synuclein (α‐syn) CSF levels were analyzed in 319 subjects, among whom 57 also underwent an amyloid PET scan. We also analyzed longitudinal clinical data from 239 subjects. Results: Emerging CSF markers, especially ng/BACE‐1 ratio (area under the curve = 0.77) and their combinations with core AD CSF markers (all AUCs >0.85), showed high accuracy to discriminate amyloid PET positivity. Subjects with AD had higher CSF BACE‐1, ng, and α‐syn levels than those with non‐AD dementia. CSF t‐tau/α‐syn ratio was higher in subjects with dementia with Lewy bodies than in those with frontotemporal dementia. Most emerging/core AD ratios predicted a faster conversion from mild cognitive impairment (MCI) stage to AD and appeared to be helpful when core AD CSF markers were discordant. In addition, the rate of cognitive decline was associated with all CSF core AD markers, several emerging/core AD two‐marker ratios, and CSF ng levels. Conclusions: These results suggest that emerging biomarkers in conjunction with core AD markers improve diagnosis of AD, are associated with the conversion from MCI into AD, and predict a faster progression of dementia.

ORIGINAL ARTICLE

Background and purpose

Epidemiological studies have reported an association between famine exposure and increased risk of cardiovascular disease. However, it is unclear whether fetal exposure to the Great Chinese Famine of 1959 to 1961 was associated with risk of ischemic stroke in midlife.

Methods

A total of 17,787 participants of the Kailuan study, who were free of cardiovascular disease and cancer at baseline (2006) were enrolled in the study. All participants were divided into three groups: unexposed (born between 1 October 1962 and 30 September 1964, used as the reference group in current analyses), fetal exposure (born between 1 October 1959 and 30 September 1961), and early childhood exposure (born between 1 October 1956 and 30 September 1958). Incident ischemic stroke cases between 2006 and 2017 were confirmed by review of medical records. Cox proportional hazards regression was applied to analyze the effect of fetal famine exposure on ischemic stroke risk.

Results

During the mean (10.4 ± 2.2) years of follow‐up, 547 incident ischemic stroke cases were identified. After adjustment for potential confounders, the hazard ratio (HR) for ischemic stroke was 1.45, and the 95% confidence interval (CI) was 1.14, 1.84 for fetal famine–exposed compared with unexposed individuals. Similar associations were observed in men (adjusted HR: 1.40; 95% CI: 1.08, 1.80) and overweight individuals (adjusted HR: 1.56; 95% CI: 1.18, 2.07), but not in their counterparts. The results of the early childhood–exposed group were similar to the above.

Conclusions

Our findings support an association between fetal malnutrition and higher risk of ischemic stroke in adulthood.

ORIGINAL ARTICLE

Background and purpose

The CHADS‐VASc score has immense prognostic value in patients with embolic stroke of undetermined source (ESUS). We aimed to determine the usefulness of advanced renal dysfunction and its addition to the CHADS‐VASc score in improving predictive accuracy.

Methods

In total, 3775 ESUS patients were enrolled from a nationwide hospital‐based prospective study. Advanced renal dysfunction was defined as estimated glomerular filtration rate <30 ml/min per 1.73 m or patients under dialysis. Clinical outcomes included recurrent stroke and 1‐year all‐cause mortality. Poor functional outcome was defined as a modified Rankin Scale >2 at first‐, third‐, and sixth‐month post‐stroke. The renal (R)‐CHADS‐VASc score was derived by including advanced renal dysfunction in the CHADS‐VASc score. Risk stratification improvement after including advanced renal dysfunction was assessed using C statistic, integrated discrimination improvement (IDI), and category‐free net reclassification index (NRI).

Results

After adjusting for confounding factors and CHADS‐VASc score, advanced renal dysfunction showed significant associations with all‐cause mortality (HR: 2.88, 95% CI: 1.92–4.34) and poor functional outcome at third‐ (OR: 2.69, 95% CI: 1.47–4.94) and sixth‐month post‐stroke (OR: 2.67, 95% CI: 1.47–4.83). IDI and NRI showed that incorporating advanced renal dysfunction significantly improved risk discrimination over the original CHADS‐VASc score. R‐CHADS‐VASc score ≥2 increased risk by 1.94‐fold (95% CI: 1.15–3.27) for all‐cause mortality, and ≥4 increased risk by 1.62‐fold (95% CI: 1.05–2.50) of poor functional outcome at third‐month post‐stroke and by 1.81‐fold (95% CI: 1.19–2.75) at sixth‐month post‐stroke.

Conclusions

Advanced renal dysfunction was significantly associated with clinical and functional outcomes in ESUS patients and may improve prognostic impact of the CHADS‐VASc score.

ORIGINAL ARTICLE

Background and purpose

The aim of this study was to explore whether cystatin C (CysC) could be used as a potential predictor of clinical outcomes in acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (IV‐tPA).

Methods

We performed an observational study including a retrospective analysis of data from 125 AIS patients with intravenous thrombolysis. General linear models were applied to compare CysC levels between groups with different outcomes; logistic regression analysis and receiver‐operating characteristic curves were adopted to identify the association between CysC and the therapeutic effects.

Results

Compared with the "good and sustained benefit" (GSB) outcome group (defined as ≥4‐point reduction in National Institutes of Health Stroke Scale or a score of 0–1 at 24 h and 7 days) and the "good functional outcome" (GFO) group (modified Rankin Scale score 0–2 at 90 days), serum CysC baseline levels were increased in the non‐GSB and non‐GFO groups. Logistic regression analysis found that CysC was an independent negative prognostic factor for GSB (odds ratio [OR] 0.010;  = 0.005) and GFO (OR 0.011;  = 0.021) after adjustment for potential influencing factors. Receiver‐operating characteristic curves showed the CysC‐involved combined models provided credible efficacy for predicting post‐90‐day favorable clinical outcome (area under the curve 0.86;  < 0.001).

Conclusions

Elevated serum CysC is independently associated with unfavorable clinical outcomes after IV‐tPA therapy in AIS. Our findings provide new insights into discovering potential mediators for neuropathological process or treatment in stroke.

ORIGINAL ARTICLE

Background and purpose

To explore the feasibility of a neuroprotection trial in prodromal synucleinopathy, using idiopathic rapid eye movement sleep behavior disorder (iRBD) as the target population and I‐FP‐CIT‐SPECT as a biomarker of disease progression.

Methods

Consecutive iRBD patients were randomly assigned to a treatment arm receiving selegiline and symptomatic rapid eye movement sleep behavior disorder treatment, or to a control arm receiving symptomatic treatment only. Selegiline was chosen because of a demonstrated neuroprotection effect in animal models. Patients underwent I‐FP‐CIT‐SPECT at baseline and after 30 months on average. The clinical outcome was the emergence of parkinsonism and/or dementia. A repeated‐measures general linear model (GLM) was applied using group (control and treatment) as ”between” factor, and both time (baseline and follow‐up) and regions (I‐FP‐CIT‐SPECT putamen and caudate uptake) as the ”within” factors, adjusting for age.

Results

Thirty iRBD patients completed the study (68.2 ± 6.9 years; 29 males; 21% dropout rate), 13 in the treatment arm, and 17 in the control arm. At follow‐up (29.8 ± 9.0 months), three patients in the control arm developed dementia and one parkinsonism, whereas two patients in the treatment arm developed parkinsonism. Both putamen and caudate uptake decreased over time in the control arm. In the treatment arm, only the putamen uptake decreased over time, whereas caudate uptake remained stable. GLM analysis demonstrated an effect of treatment on the I‐FP‐CIT‐SPECT uptake change, with a significant interaction between the effect of group, time, and regions ( = 0.004).

Conclusions

A 30‐months neuroprotection study for prodromal synucleinopathy is feasible, using iRBD as the target population and I‐FP‐CIT‐SPECT as a biomarker of disease progression.

oORIGINAL ARTICLE

Background and purpose

Cardiac involvement is observed in about 80% of subjects with myotonic dystrophy type 1 (DM1) and is mainly characterized by cardiac conduction and/or rhythm abnormalities (CCRAs), possibly leading to sudden cardiac death (SCD). Our objective was to investigate whether the gender difference may influence the cardiac involvement and SCD in DM1.

Methods

We analyzed prevalence and incidence of cardiological abnormalities in males versus females in 151 consecutive DM1 patients over a 35‐year follow‐up period.

Results

Fifty‐five patients, 35 males (62.5%) and 20 females (42.5%), developed some type of CCRA during the follow‐up period (mean 7.82 ± 6.21 years). CCRA overall, and specifically cardiac conduction abnormalities (CCAs), were significantly more frequent in males than in females ( = 0.043 and  = 0.031, respectively). CCRAs progressed in 16 males (45.7%) and six females (30%). Twenty‐four patients, 14 males (25.0%) and 10 females (21.3%), died during the follow‐up. Nine of them, six males (10.7%) and three females (6.4%), had SCD. After correction for Muscular Impairment Rating Scale progression, cytosine thymine‐guanine expansion, and follow‐up duration, a higher prevalence of CCAs was independently associated with male gender ( = 0.039), but independent association with gender was not detected for CCRAs overall, cardiac rhythm abnormalities, and SCD prevalence, even if prevalence was higher in males than females.

Conclusions

The overall risk of occurrence of CCAs in DM1 is significantly higher in males than females regardless of genetic background and disease severity and progression. Moreover, the data also suggest a similar impact for male gender for CCRAs overall, CCAs, and SCD even if not statistically significant.

ORIGINAL ARTICLE

Background and purpose

Some acute ischaemic stroke (AIS) patients do not display established vascular risk factors (EVRFs). The aim was to assess their clinical characteristics, stroke subtype etiological classification and long‐term outcome.

Methods

All consecutive AIS patients from the Acute Stroke Registry of Lausanne (2003–2018) were retrospectively analyzed with complete assessment of the following EVRFs: hypertension, diabetes, major cardioembolic sources, dyslipidemia, smoking, obesity, alcohol abuse, previous stroke/transient ischaemic attack and depression/psychosis. Patients without EVRFs were compared to patients with one or more EVRFs using appropriate statistical models.

Results

Of 4889 included patients, 103 (2.1%) had no EVRFs. In multiple regression analysis, patients without EVRFs were significantly younger (odds ratio [OR] 0.13; 95% confidence interval [CI] 0.08–0.20) and had more multiterritorial strokes (OR 3.38; 95% CI 1.26–9.05). Strokes were more often related to patent foramen ovale (PFO) (OR 3.02; 95% CI 1.44–6.32) and less to atherosclerosis, cardioembolism or small vessel disease. In patients <55 years old, PFO (OR 2.76; 95% CI 1.50–5.08) and contraceptive use in females (OR 2.75; 95% CI 1.40–5.41) were more frequent, whereas sleep apnea syndrome (OR 0.09; 95% CI 0.01–0.63) was less. In patients ≥55 years, female sex (OR 2.84; 95% CI 1.43–5.65) and active cancer (OR 3.27; 95% CI 1.34–7.94) were more prevalent. At 12 months, patients without EVRFs had worse adjusted functional outcome (Rankin shift OR 0.63; 95% CI 0.42–0.95) and higher rate of recurrence and death (adjusted hazard ratio 2.11; 95% CI 1.19–3.74).

Conclusions

In a consecutive cohort of AIS patients, only 2% showed no EVRFs. PFO and contraceptive use exhibited a strong association with the absence of EVRFs in younger patients and female sex and active cancer in elderly patients. Our findings highlight the importance of searching for previously unknown risk factors and/or unusual stroke mechanisms in patients without EVRFs.

ORIGINAL ARTICLE

Background

Previous studies reported reduced decision‐making abilities for patients with multiple sclerosis (MS) relative to healthy controls (HC). This study aimed to evaluate whether these problems arise when sampling information or when pondering about the evidence collected.

Methods

In a cross‐sectional, controlled study, 43 relapsing‐remitting MS patients (RRMS; Expanded Disability Status Scale 1.5, range 0–4) and 53 HC performed an information sampling task (‘beads task’), a health‐related framing task, and neuropsychological background tests.

Results

In the beads task, patients collected as much information as HC prior to a decision. However, there were twice as many patients as HC making irrational decisions, that is, decisions against the evidence collected (RRMS: 26/43, 60%; HC: 16/53, 30%;  = 0.003). Compared to HC, patients also showed a stronger framing effect, that is, they were more strongly biased by the way health‐related information was presented ( < 0.05, Cohen's  = 0.5). Overall, the framing effect predicted whether a participant would make irrational decisions (OR 2.12, 95% CI 1.29–3.49,  < 0.001).

Conclusions

Predecisional information sampling is intact in RRMS. However, compared to HC, patients are more likely to make irrational decisions and to be biased by the way health‐related information is framed. This warrants caution in communication, especially in the medical context, with patients.

ORIGINAL ARTICLE

Background and purpose

Cancer treatments have deleterious effects on both brain structure and the cognition of lung cancer patients. Physical activity (PA) has beneficial effects on the cognition of healthy adults by eliciting brain plasticity, especially on the medial temporal lobe (hippocampus). Therefore, the aim was to study the neuroprotective effects of a 3‐month PA programme (PAP) on the brain structure and cognitive performance of lung cancer patients.

Methods

Twelve patients (seven non‐small‐cell lung cancer [NSCLC] patients following chemotherapy, five small‐cell lung cancer [SCLC] patients following chemotherapy and prophylactic cranial irradiation) agreed to complete the PAP and underwent baseline and 3‐month (post‐PAP) brain magnetic resonance imaging and neuropsychological evaluations (PAP group). Twelve lung cancer patients (seven NSCLC, five SCLC; non‐PAP group) and 12 healthy sex‐, age‐ and education‐matched controls were recruited and completed two evaluations separated by the same amount of time. A region of interest voxel‐based morphometry analysis focused on bilateral hippocampi was performed.

Results

Physical activity programme patients presented greater grey matter volume (GMV) across time in both hippocampi. Moreover, it was observed that SCLC patients in both the PAP and non‐PAP groups presented a time‐dependent GMV loss in bilateral hippocampi that was not significant in NSCLC patients. Importantly, the PA intervention decreased the magnitude of that GMV loss, becoming thus especially beneficial at the brain structural level for SCLC patients.

Conclusions

Our study demonstrates, using a neuroimaging approach for the first time, that PA is able to stop the deleterious effects of systemic chemotherapy and brain radiation on brain structures of the lung cancer population, especially in SCLC patients.

ORIGINAL ARTICLE

Background and purpose

To examine the effect of delayed compared to early planning of shunt surgery on survival, in patients with idiopathic normal pressure hydrocephalus (iNPH), a long‐term follow‐up case–control study of patients exposed to a severe delay of treatment was performed.

Methods

In 2010–2011 our university hospital was affected by an administrative and economic failure that led to postponement of several elective neurosurgical procedures. This resulted in an unintentional delay of planning of treatment for a group of iNPH patients, referred to as iNPH ( = 33, waiting time for shunt surgery 6–24 months). These were compared to patients treated within 3 months, iNPH ( = 69). Primary outcome was mortality. Dates and underlying causes of death were provided by the Cause of Death Registry. Survival was analysed by Kaplan–Meier plots and a Cox proportional hazard model adjusted for potential confounders.

Results

Median follow‐up time was 6.0 years. Crude 4‐year mortality was 39.4% in iNPH compared to 10.1% in iNPH ( = 0.001). The adjusted hazard ratio in iNPH was 2.57; 95% confidence interval 1.13–5.83,  = 0.024. Causes of death were equally distributed between the groups except for death due to malignancy which was not seen in iNPH but in 4/16 cases in iNPH ( = 0.044).

Conclusions

The present data indicate that shunt surgery is effective in iNPH and that early treatment increases survival.

ORIGINAL ARTICLE

Background and purpose

Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS.

Methods

One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected.

Results

TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of TuMS patients presented with the involvement of more than one functional system and 24.5% of them with multiple TDLs. TDLs most frequently presented with an infiltrative MRI pattern (38.7%). Cerebrospinal fluid immunoglobulin G oligoclonal bands were often demonstrated (76.6%). In 25.3% of the cases, more than one acute‐phase treatment was administered, and almost one‐half of the patients (46.6%) were treated with high‐efficacy treatments. After a median follow‐up of 2.3 years (range: 0.1–10.7 years, IQR: 3.4 years), the median Expanded Disability Status Scale (EDSS) score was 1.5 (range: 0–7, IQR: 2). Independent risk factors for reaching an EDSS score ≥3 were a higher age at onset (odds ratio [OR]: 1.08, 95% confidence interval [CI]: 1.03–1.14,  < 0.01), a higher number of TDLs (OR: 1.67, 95% CI: 1.02–2.74,  < 0.05) and the presence of infiltrative TDLs (OR: 3.34, 95% CI: 1.18–9.5,  < 0.001) at baseline.

Conclusions

The management of TuMS might be challenging because of its peculiar characteristics. Large prospective studies could help to define the clinical characteristics and the best treatment algorithms for people with TuMS.

ORIGINAL ARTICLE

Objective

This study aimed to examine echolalia and its related symptoms and brain lesions in primary progressive aphasia (PPA).

Methods

Forty‐five patients with PPA were included: 19 nonfluent/agrammatic variant PPA (nfvPPA), 5 semantic variant PPA, 7 logopenic variant PPA, and 14 unclassified PPA patients. We detected echolalia in unstructured conversations. An evaluation of language function and the presence of parkinsonism, grasp reflex, imitation behaviour, and disinhibition were assessed. We also measured regional cerebral blood flow (rCBF) using single‐photon emission computed tomography.

Results

Echolalia was observed in 12 nfvPPA and 2 unclassified PPA patients. All patients showed mitigated echolalia. We compared nfvPPA patients with echolalia (echolalia group) to those without echolalia (non‐echolalia group). The median age of the echolalia group was significantly lower than that of the non‐echolalia group, and the echolalia group showed a significantly worse auditory comprehension performance than the non‐echolalia group. In contrast, the performance of repetition tasks was not different between the two groups. The prevalence of imitation behaviour in the echolalia group was significantly higher than that in the non‐echolalia group. The rCBFs in the bilateral pre‐supplementary motor area and bilateral middle cingulate cortex in the echolalia group were significantly lower than those in the non‐echolalia group.

Conclusions

These findings suggest that echolalia is characteristic of nfvPPA patients with impaired comprehension. Reduced inhibition of the medial frontal cortex with release activity of the anterior perisylvian area account for the emergence of echolalia.

ORIGINAL ARTICLE

Background and purpose

Defining refractory myasthenia gravis is important, as this can drive clinical decision making, for example, by escalating treatments in refractory individuals. There are several definitions of refractory myasthenia, and their performances have not been compared. Having valid and reliable criteria can help select patients in whom more aggressive treatments may be needed.

Methods

We applied five different refractory myasthenia criteria (Drachman, Mantegazza, Suh, the International Consensus Guideline (ICG), and the randomised controlled trial of eculizumab in refractory, anti‐acetylcholine receptor positive, generalised myasthenia gravis (REGAIN), to a cohort of 237 patients. We compared the proportion of refractory patients among different criteria and their scores on disease severity, fatigue, and quality‐of‐life (QoL) scales. We also assessed the agreement for each criterion between two trained assessors.

Results

The Drachman, Mantegazza, and Suh criteria resulted in high proportions of refractory individuals (40.1%, 39.2%, and 38.8%, respectively), compared with the ICG and REGAIN criteria (9.7% and 3.0%, respectively). Refractory patients by the ICG and REGAIN criteria had worse disease severity, QoL, and fatigue scores, compared with patients classified as refractory by other criteria. All criteria had high agreement between raters (between 70% and 100%).

Conclusions

There is high variability in the proportion of refractory myasthenia gravis patients depending on the criteria used, with ICG and REGAIN criteria capturing patients with worse disease severity. This reflects conceptual differences as to what refractory means. Further multicenter studies are needed to determine appropriate criteria for refractory myasthenia gravis.

ORIGINAL ARTICLE

Background and purpose

The purpose was to assess the prognostic role of neck muscle weakness at diagnosis in amyotrophic lateral sclerosis (ALS) patients with respect to survival and respiratory impairment.

Methods

A retrospective cohort study was conducted. All ALS patients seen in the Turin ALS Centre from 2007 to 2014 were included. Muscle strength at diagnosis was evaluated using the Medical Research Council (MRC) scale. Survival was considered as the time from diagnosis to death or tracheostomy; time to respiratory impairment was considered as the interval from diagnosis to the first event amongst an ALS Functional Rating Scale revised item 10 <4, forced vital capacity <70%, start of non‐invasive ventilation or tracheostomy. Time from diagnosis to dysarthria, dysphagia and walking impairment were considered as secondary outcomes. Cox proportional hazard regression models adjusted for sex, age at diagnosis, diagnostic delay, onset site, genetics status and the MRC scores of other muscle groups were used to assess the prognostic role of neck muscles.

Results

A total of 370 patients were included in the study. Fifty‐nine (15.9%) patients showed neck flexor weakness at diagnosis; MRC values were mostly in agreement for neck extensors. Neck flexors were the only muscles able to predict survival (hazard ratio 0.49, 95% confidence interval 0.28–0.86;  = 0.01). Furthermore, neck flexor normal strength decreased the risk of respiratory impairment (hazard ratio 0.46, 95% confidence interval 0.22–0.96;  = 0.04) but did not influence any secondary outcomes.

Discussion

Neck flexor weakness at diagnosis predicts survival and respiratory impairment in ALS. This result could be valuable for both planning of patients’ interventions and clinical trials’ design.

ORIGINAL ARTICLE

Background

Neurology is often perceived as a difficult discipline by medical students, yet it is an essential part of medical training. While the most common disorders of the nervous system can be observed in the outpatient setting, positive neurological signs are more likely to be found in neurology wards. We aimed to compare the impact of a neurology outpatient versus inpatient rotation setting on the grades obtained by medical students as a proxy measure of the learning outcomes.

Methods

We compared the results obtained by fourth year medical students in practical (OSCE) and multiple choice question (MCQ) exams in neurology, between students whose main (total of 24 h contact) teaching allocation was either the outpatient or inpatient setting, controlling for students’ gender, teacher, academic year and student’ previous achievement (measured by their scores on practical evaluation).

Results

A total of 1127 students were included, of whom 644 (57.14%) were allocated mainly to the neurology ward and 483 (42.86%) to the outpatient clinic. Students assigned to the ward obtained significantly higher grades in the OSCE and MCQ exams than those placed in the outpatient clinic. Teaching setting was an independent predictor of both classifications after adjustment.

Conclusions

The teaching setting had a significant impact on the learning outcomes. This may be due to a higher likelihood of observing abnormal neurological signs or to more student‐centered teaching on the ward. These results highlight the importance of a balanced distribution of students by different clinical settings.

ORIGINAL ARTICLE

Background and purpose

Distal hereditary motor neuropathies (dHMNs) are a heterogeneous group of disorders characterized by degeneration of the motor component of peripheral nerves. Currently, only 15% to 32.5% of patients with dHMN are characterized genetically. Additionally, the prevalence of these genetic disorders is not well known. Recently, biallelic mutations in the sorbitol dehydrogenase gene () have been identified as a cause of dHMN, with an estimated frequency in undiagnosed cases of up to 10%.

Methods

In the present study, we included 163 patients belonging to 108 different families who were diagnosed with a dHMN and who underwent a thorough genetic screening that included next‐generation sequencing and subsequent Sanger sequencing of .

Results

Most probands were sporadic cases (62.3%), and the most frequent age of onset of symptoms was 2 to 10 years (28.8%). A genetic diagnosis was achieved in 37/108 (34.2%) families and 78/163 (47.8%) of all patients. The most frequent cause of distal hereditary motor neuropathies were mutations in (10.4%), (9.8%), (8.0%), and (6.7%) genes. In addition, 3.1% of patients were found to be carriers of biallelic mutations in . Mutations in another seven genes were also identified, although they were much less frequent. Eight new pathogenic mutations were detected, and 17 patients without a definite genetic diagnosis carried variants of uncertain significance. The calculated minimum prevalence of dHMN was 2.3 per 100,000 individuals.

Conclusions

This study confirms the genetic heterogeneity of dHMN and that biallelic mutations are a cause of dHMN in different populations.

EDITORIAL

Echolalia: Paying attention to a forgotten clinical feature of primary progressive aphasia

EDITORIAL

Setting and outcomes in neurology teaching: Where should teaching be addressed?

LETTER TO THE EDITOR

Cystatin C and intravenous thrombolysis

Editorial

Broadening the genetic spectrum of distal hereditary motor neuropathy

LETTER TO THE EDITOR

Cardiac sources of cerebral embolism in people with migraine

CASE STUDY

Abstract

We present the case of a patient with a sleep disturbance attributed to the exploding head syndrome, recently redefined as episodic cranial sensory shock. The patient, who suffered with concomitant migraine, was treated for headache prevention with daily single‐pulse transcranial magnetic stimulation (sTMS). Following treatment, he reported a significant reduction in the episodes of exploding head syndrome, albeit not of his migraine. Neurologists could consider sTMS in the management of patients troubled by episodic cranial sensory shock, as it is a safe and noninvasive treatment that might provide benefit for this benign but occasionally bothersome parasomnia.

EDITORIAL

: Merging phenotypes and disease mechanisms in Charcot‐Marie‐Tooth neuropathy and lower motor neuron disease

LETTERS TO THE EDITOR

Reply to Schmitt HJ et al.: ‘Response to: “Patients with breakthrough tick‐borne encephalitis suffer a more severe clinical course and display extensive magnetic resonance imaging changes”’

EDITORIAL

One year later …